Virios Therapeutics (VIRI, Financial) experienced a pre-market surge of over 33%, with shares trading at $0.183. The company announced a definitive share exchange agreement for a merger with Wex Pharmaceuticals, a subsidiary of Conyer Life Science International. This merger will be executed entirely through a stock exchange.
Post-merger, Virios Therapeutics will rebrand as Dogwood Therapeutics.